Physician profile
Brooks Mays
NPI 1124134010
$40,382.05
in general payments reported to CMS, 2019-2025
59 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $5,020 · 2021: $3,438 · 2022: $629 · 2023: $2,454 · 2024: $1,872 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,392 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,392.39 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24,476.36 | 2019-2020 | |
| Abbvie INC. | $4,774.79 | 2019-2025 | |
| Lilly USA, LLC | $1,695.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,315.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $829.95 | 2019-2025 | |
| Amgen INC. | $631.36 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.19 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $545.78 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $529.04 | 2019-2025 | Farxiga |
| Mannkind Corporation | $352.99 | 2019-2025 | Afrezza |
| Insulet Corporation | $339.10 | 2019-2024 | Omnipod |
| Abbott Laboratories | $336.02 | 2023-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $324.86 | 2019-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $279.29 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $272.47 | 2021-2025 | Isturisa, Signifor Lar |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $226.81 | 2021-2024 | Minimed 780g |
| Ibsa Pharma INC. | $214.93 | 2019-2025 | Tirosint, Licart, Licart |
| Merck Sharp & Dohme LLC | $197.09 | 2019-2021 | |
| Acella Pharmaceuticals, LLC | $192.78 | 2019-2023 | NP Thyroid 60 |
| Valeritas, INC. | $186.70 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $138.80 | 2023-2025 | Imcivree, Imcivree |
| Shire North American Group INC | $118.08 | 2019 | |
| Amneal Pharmaceuticals LLC | $113.77 | 2021-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $108.43 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $108.00 | 2022-2024 | |
| Cequr Corporation | $106.07 | 2023-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $100.44 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Kyowa Kirin, INC. | $92.91 | 2023-2024 | Crysvita |
| Ascendis Pharma Endocrinology INC | $89.62 | 2023-2025 | Yorvipath |
| Medtronic Minimed, INC. | $75.14 | 2019 | |
| Genzyme Corporation | $71.00 | 2020 | |
| Azurity Pharmaceuticals, INC. | $67.90 | 2023-2024 | Adthyza, Horizant, Horizant |
| Arbor Pharmaceuticals, INC. | $67.36 | 2019-2021 | |
| Aytu Biopharma, INC. | $65.25 | 2019 | |
| Tandem Diabetes Care, INC. | $64.55 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $61.91 | 2023 | Tepezza |
| Eusa Pharma (US) LLC | $57.10 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $54.94 | 2019-2021 | |
| Almatica Pharma LLC | $52.45 | 2025 | Teriparatide |
| Neurocrine Biosciences, INC. | $43.58 | 2024-2025 | Crenessity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.39 | 2019 | |
| Currax Pharmaceuticals LLC | $39.51 | 2019-2023 | Nexletol |
| Clarus Therapeutics INC. | $28.60 | 2021 | |
| Amarin Pharma, INC. | $28.16 | 2020-2021 | |
| Sequel Med Tech, LLC | $25.15 | 2025 | Twiist |
| Rgh Enterprises LLC | $22.64 | 2025 | |
| Antares Pharma, INC. | $19.55 | 2019 | |
| Averitas Pharma INC. | $19.49 | 2023 | Qutenza |
| Grt US Holding, INC. | $19.46 | 2021 | |
| Daiichi Sankyo INC. | $18.62 | 2019 | |
| Amryt Pharma Holdings LTD | $17.06 | 2023 | Mycapssa |
| Dexcom, INC. | $16.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.11 | 2021 | |
| Verity Pharmaceuticals INC. | $14.84 | 2025 | Tlando |
| Inspire Medical Systems, INC. | $14.73 | 2024 | Inspire |
| Acerus Pharmaceuticals Corporation | $14.13 | 2020 | |
| Esperion Therapeutics, INC. | $13.81 | 2025 | Nexletol |
| Lifescan, INC. | $13.69 | 2021 | |
| Nevro Corp. | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooks Mays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.